Calluna Pharma: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Calluna Pharma
Largest movements
- Cash -€33,028
down €33,028 (-33.4%), from €99,024 to €65,996
mainly Net result for the year (-€32,468) and Receivables within one year (-€586)
- Profit (loss) carried forward -€32,468
down €32,468 (-39.5%), from €82,258 to €49,791
- Other operating charges -€8,401
down €8,401 (-85.9%), from €9,779 to €1,379
- Gross operating margin -€978
down €978 (-3.2%), from -€30,207 to -€31,185
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €105,639 | €73,235 | -€32,405 | -30.7% |
| Current assets | 29/58 | €105,639 | €73,235 | -€32,405 | -30.7% |
| Amounts receivable within one year | 40/41 | €6,615 | €7,201 | +€586 | +8.9% |
| Other amounts receivable | 41 | €6,615 | €7,201 | +€586 | +8.9% |
| Cash at bank and in hand | 54/58 | €99,024 | €65,996 | -€33,028 | -33.4% |
| Deferred charges and accrued income | 490/1 | - | €38 | +€38 | |
| Total equity and liabilities | 10/49 | €105,639 | €73,235 | -€32,405 | -30.7% |
| Equity | 10/15 | €102,718 | €70,251 | -€32,468 | -31.6% |
| Contributions | 10/11 | €18,600 | €18,600 | = | 0.0% |
| Reserves | 13 | €1,860 | €1,860 | = | 0.0% |
| Distributable reserves | 133 | €1,860 | €1,860 | = | 0.0% |
| Profit (loss) carried forward | 14 | €82,258 | €49,791 | -€32,468 | -39.5% |
| Amounts payable | 17/49 | €2,921 | €2,984 | +€63 | +2.1% |
| Amounts payable within one year | 42/48 | €2,921 | €2,973 | +€51 | +1.8% |
| Trade debts | 44 | €2,921 | €2,973 | +€51 | +1.8% |
| Suppliers | 440/4 | €2,921 | €2,973 | +€51 | +1.8% |
| Taxes, remuneration and social security | 45 | €0 | - | = | |
| Taxes | 450/3 | €0 | - | = | |
| Accrued charges and deferred income | 492/3 | - | €11 | +€11 | |
| Other operating charges | 640/8 | €9,779 | €1,379 | -€8,401 | -85.9% |
| Gross operating margin | 9900 | -€30,207 | -€31,185 | -€978 | -3.2% |
| Operating profit (loss) | 9901 | -€39,986 | -€32,564 | +€7,422 | +18.6% |
| Financial income | 75/76B | €248 | €339 | +€91 | +36.7% |
| Recurring financial income | 75 | €248 | €339 | +€91 | +36.7% |
| Financial charges | 65/66B | €114 | €118 | +€5 | +4.2% |
| Recurring financial charges | 65 | €114 | €118 | +€5 | +4.2% |
| Profit (loss) for the period before taxes | 9903 | -€39,852 | -€32,343 | +€7,509 | +18.8% |
| Income taxes | 67/77 | -€124 | €124 | +€249 | |
| Profit (loss) for the period | 9904 | -€39,727 | -€32,468 | +€7,260 | +18.3% |
| Profit (loss) for the period to be appropriated | 9905 | -€39,727 | -€32,468 | +€7,260 | +18.3% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 17 October 2026 via checked.be.